Pralatrexate

In the US, Pralatrexate (pralatrexate systemic) is a member of the drug class antimetabolites and is used to treat Lymphoma, Non-Hodgkin's Lymphoma and Peripheral T-cell Lymphoma.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01BA05

CAS registry number (Chemical Abstracts Service)

0146464-95-1

Chemical Formula

C23-H23-N7-O5

Molecular Weight

477

Therapeutic Category

Antineoplastic agent

Chemical Names

N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid (IUPAC)

N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid (WHO)

(2S)-2-[[4-[(1RS)-1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid (USAN)

10-Propargyl-10-deazaaminopterin

L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]- (USAN)

Foreign Names

  • Pralatrexatum (Latin)
  • Pralatrexat (German)
  • Pralatrexate (French)
  • Pralatrexato (Spanish)

Generic Names

  • Pralatrexate (OS: USAN)
  • PDX (IS)
  • UNIIA8Q8I19Q20 (IS)

Brand Name

International Drug Name Search

Glossary

TermDefinition
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide
(web2)